key: cord-0765867-nr9je56u
authors: Izcovich, Ariel; Ragusa, Martín Alberto; Tortosa, Fernando; Lavena Marzio, María Andrea; Agnoletti, Camila; Bengolea, Agustín; Ceirano, Agustina; Espinosa, Federico; Saavedra, Ezequiel; Sanguine, Verónica; Tassara, Alfredo; Cid, Candelaria; Catalano, Hugo Norberto; Agarwal, Arnav; Foroutan, Farid; Rada, Gabriel
title: Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review
date: 2020-11-17
journal: PLoS One
DOI: 10.1371/journal.pone.0241955
sha: 9f25eb839c4053df9684e2b1b86aa25c2004304f
doc_id: 765867
cord_uid: nr9je56u

BACKGROUND AND PURPOSE: The objective of our systematic review is to identify prognostic factors that may be used in decision-making related to the care of patients infected with COVID-19. DATA SOURCES: We conducted highly sensitive searches in PubMed/MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase. The searches covered the period from the inception date of each database until April 28, 2020. No study design, publication status or language restriction were applied. STUDY SELECTION AND DATA EXTRACTION: We included studies that assessed patients with confirmed or suspected SARS-CoV-2 infectious disease and examined one or more prognostic factors for mortality or disease severity. Reviewers working in pairs independently screened studies for eligibility, extracted data and assessed the risk of bias. We performed meta-analyses and used GRADE to assess the certainty of the evidence for each prognostic factor and outcome. RESULTS: We included 207 studies and found high or moderate certainty that the following 49 variables provide valuable prognostic information on mortality and/or severe disease in patients with COVID-19 infectious disease: Demographic factors (age, male sex, smoking), patient history factors (comorbidities, cerebrovascular disease, chronic obstructive pulmonary disease, chronic kidney disease, cardiovascular disease, cardiac arrhythmia, arterial hypertension, diabetes, dementia, cancer and dyslipidemia), physical examination factors (respiratory failure, low blood pressure, hypoxemia, tachycardia, dyspnea, anorexia, tachypnea, haemoptysis, abdominal pain, fatigue, fever and myalgia or arthralgia), laboratory factors (high blood procalcitonin, myocardial injury markers, high blood White Blood Cell count (WBC), high blood lactate, low blood platelet count, plasma creatinine increase, high blood D-dimer, high blood lactate dehydrogenase (LDH), high blood C-reactive protein (CRP), decrease in lymphocyte count, high blood aspartate aminotransferase (AST), decrease in blood albumin, high blood interleukin-6 (IL-6), high blood neutrophil count, high blood B-type natriuretic peptide (BNP), high blood urea nitrogen (BUN), high blood creatine kinase (CK), high blood bilirubin and high erythrocyte sedimentation rate (ESR)), radiological factors (consolidative infiltrate and pleural effusion) and high SOFA score (sequential organ failure assessment score). CONCLUSION: Identified prognostic factors can help clinicians and policy makers in tailoring management strategies for patients with COVID-19 infectious disease while researchers can utilise our findings to develop multivariable prognostic models that could eventually facilitate decision-making and improve patient important outcomes. SYSTEMATIC REVIEW REGISTRATION: Prospero registration number: CRD42020178802. Protocol available at: https://www.medrxiv.org/content/10.1101/2020.04.08.20056598v1.

Introduction COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus [1] . It was first identified in Wuhan, China, on December 31, 2019 [2] ; five months later, more than six million cases had been identified across 215 countries [3] . On March 11, 2020, WHO characterised the COVID-19 outbreak as a pandemic [1] . While the majority of cases present with mild symptoms, a minority progress to acute respiratory illness and hypoxia requiring hospitalization, and a subset develop acute respiratory distress syndrome, multi-organ failure or have fatal outcomes [4] . The case fatality rate reported across countries, settings and age groups is highly variable, ranging from about 0.5% to 10% [5] . In hospitalised patients it has been reported to be higher than 20% [6] .

Prognostic factors (stand-alone or combined in risk assessment models) may guide the stratification of patients with SARS-CoV-2 infectious disease based on their risk of severe disease or death. This risk stratification may subsequently guide optimised management and resource utilisation strategies in the care of these patients.

Although multiple prognostic factors have been proposed and some have been accepted as "established" by the scientific community (i.e age), the predictive value of most of these potential prognostic factors has not been robustly evaluated and remains uncertain. As pointed out by Wynants et.al: "unreliable predictors could cause more harm than benefit in guiding clinical decisions" [7] . For example, aggressive and risky interventions might be attempted if the risk of poor outcomes are inaccurately defined as high based on unreliable predictors.

Using innovative and agile processes supported by advanced evidence synthesis tools and collaborative efforts across several international research groups, this systematic review aims to provide a rigorous summary of the evidence available on prognostic factors that may be used in decision-making related to the care of patients infected with COVID-19.

We published [8] and registered the protocol for this systematic review with PROSPERO (CRD42020178802).

We conducted highly sensitive searches in PubMed/MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase. The searches covered the period from the inception date of each database until April 28, 2020. No study design, publication status or language restriction were applied.

Detailed strategies for each database are reported in the S1 Text.

In order to identify articles that might have been missed in the electronic searches, we reviewed the reference list of each included study and performed cross citation in Google Scholar using each included study as the index reference.

Four reviewers working independently and in duplicate, performed study selection, including screening of titles and abstracts and of potentially eligible full-text articles. Reviewers resolved disagreements by discussion.

We included studies examining individual prognostic factors or risk assessment models based on the typologies of prognosis proposed by Iorio and colleagues [9] and the PROGnosis RESearch Strategy (PROGRESS) Group framework [10] without applying any restrictions based on analytical methods (i.e performing multivariable analysis).

Specifically, we included studies that evaluated patients with confirmed SARS-CoV-2 infectious disease regardless of the healthcare setting (i.e ambulatory or inpatients) and of baseline disease severity. We investigated all candidate prognostic factors reported by individual studies and compared patients exposed (the factor was present) with patients unexposed (the factor was absent) to each one of those factors.We considered studies that assessed mortality or severe COVID-19 disease as outcomes and accepted the author's definitions of the latter. When severe COVID-19 disease was reported as a multi-categorical scale, we used the most severe category. Additionally, when severe COVID-19 disease was not reported as an outcome, we considered ICU requirement, invasive mechanical ventilation (IVM) and acute respiratory distress syndrome (ARDS) as surrogate outcomes.

For each eligible study, five pairs of reviewers, independently, abstracted the following information on study characteristics (year of publication, country, medical center and time period in which the study was conducted); population characteristics (sample size, context in which the study was conducted and other population characteristics); description of prognostic factors and outcomes and their definitions; and study results (measures of association or crude event rates for every candidate prognostic factor and outcome reported).

Two reviewers assessed the risk of bias of individual included studies independently and in duplicate. Discrepancies were resolved by consensus. We used the Quality in Prognosis Studies (QUIPS) tool for prognostic factor studies [11] which considers population characteristics, attrition, prognostic factor and outcome measurement and potential residual confounding. For "study confounding summary" and "statistical analysis and presentation domains", in order to assess adequacy of the multivariable models, we considered appropriate model adjustment as based on inclusion of age, one comorbidity (e.g diabetes) and one parameter of disease severity (e.g. respiratory rate) at minimum.

We presented the results of individual prognostic factors in both tabular and narrative formats. We standardized the units of measurement for each prognostic factor, unifying the direction of the predictors and adjusting the weights of the studies, and calculated crude effect estimates when not provided [12] . When possible, we meta-analysed all prognostic factors whose association with the selected outcomes of interest was explored and were reported by more than one study. We used the generic inverse variance-based method to produce an overall measure of association and random-effect models based on the DerSimonian-Laird method provided by the metafor package for R software [13] .

For every candidate prognostic factor, we presented the measure of association as odds ratios (ORs) and their corresponding 95% confidence intervals (CI). In studies that reported the measure of association as a hazard ratio (HR) or risk ratio (RR), we converted them to ORs using the baseline risk (death rate or incidence of severe COVID-19 out of the total sample) reported in the studies [14, 15] . For dichotomous variables, we used the crude event rate to calculate ORs when no measures of association were provided. We excluded information on continuous variables for which no measures of association were available. We also calculated absolute risk differences (RDs) that can be attributed to every individual candidate prognostic factor by applying the ORs to estimated baseline risks (see below "Baseline risks"). When the same candidate prognostic factor was assessed in alternative ways (e.g. dichotomic and continuous) we used the one for which we found better certainty of evidence.

For every explored candidate variable, we performed sensitivity analysis excluding high risk of bias studies and studies that did not report adjusted estimates. In cases where the effect estimates provided by the primary analysis and the sensitivity analysis significantly differed, we either presented the moderate/low risk of bias-adjusted estimates or the primary analysis estimates but rated down certainty of the evidence because for risk of bias (see below). In addition, when we observed inconsistent results for disease severity outcome, we performed subgroup analyses accounting for outcome definition (i.e severity scale vs. IVM vs. ARDS) as a potential source of heterogeneity.

depending on the grading of the individual domains [16] . See S1 Text for a detailed description of the certainty of the evidence assessment.

To define which candidate variables provide valuable prognostic information we adopted a minimally contextualized approach [17] . To this end, we arbitrarily set thresholds to define important incremental increase in the risk of our outcomes. In setting those thresholds we aimed to define the minimal incremental increase in the risk of mortality or severe COVID-19 disease that could be interpreted as valuable prognostic information without considering the potential consequences of using that information in healthcare decision-making. These thresholds represent the line that separates a risk increase that is trivial from a small but important risk increase. We set those thresholds in 0.5% increase in mortality and 1% increase insevere COVID-19 disease. We performed a sensitivity analysis in which we adopted a purely noncontextualized approach [17] to assess mortality outcome. In doing so we only considered the relative measures of association and used an OR of 1 as the threshold for minimal important risk increment.

To define baseline risks we selected clinical scenarios based in the severity categories proposed by WHO [18] . To assess the prognostic value on mortality, we used the clinical scenario of a patient infected with COVID-19 with severe but not critical disease (i.e patients with respiratory failure but not invasive mechanical ventilation and/or hemodynamic support requirement). We identified one study informing prognosis in this specific subgroup with a mortality risk of 9% [19] . However, as we identified significant variability in mortality risks reported for similar clinical scenarios (i.e in the RECOVERY trial [20] mortality risk in hospitalized patients assigned to the control arm, with no baseline oxygen requirement was 14%), we performed a sensitivity analysis using a baseline risk of 26% as reported by a large cohort of non-ICU inpatients treated in 255 sites across 36 countries [6] .

To assess the prognostic value on severe COVID-19 disease, we used the clinical scenario of a patient infected with COVID-19 with non-severe disease. We identified 7 studies informing prognosis in this specific subgroup with a median risk of progression to severe or critical state of 13% [21-27]. We calculated baseline risks (risks in patients not exposed to the prognostic factor) by also considering the prevalence of every prognostic factor and the estimates of association [28] . When prevalence of prognostic factors was not available we used described baseline risks (9% for mortality and 13% for severe COVID-19 disease).

An artificial intelligence algorithm deployed in the Coronavirus/COVID-19 topic of the L. OVE platform (https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d) will provide instant notification of articles with a high likelihood of eligibility. These will be screened by paired reviewers iteratively and will conduct data extraction and iterative updates of estimates for selected prognostic factors accordingly. We will consider resubmission to a journal if there is a substantial modification on the measure of association or the certainty of the evidence for a given prognostic factor such that it is clinically significant, at the discretion of the reviewer team. This review is part of a larger project established to produce multiple parallel systematic reviews relevant to COVID-19 [29] . (Fig 1) illustrates the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. Our search identified 7631 citations of which we included 569 studies for full text assessment. 207 studies fulfilled the inclusion criteria [21, [23] [24] [25] 27, . These 207 studies, with sample sizes from 10 to 8910, enrolled a total of 75607 patients and were conducted in 12 different countries (China, USA, Canada, Spain, France, Turkey, Korea, Japan, Italy, Germany, India and Singapore). In 78 (37.7%) of the included studies a multivariable analysis was performed. In the 150 studies in which the severity of included patients was described the mean proportion of patients in each category was: non-severe disease 63.8%, severe disease 22.6%, critical disease 13.6%.

limitations in at least one domain or item. Most frequent were retrospective design, which may have introduced classification bias, and lack or inappropriate adjusted analysis. S2 Table  provides detailed judgements for each of the risk of bias domains criteria.

We investigated 96 candidate prognostic factors for mortality from 116 studies including 57044 patients. S3 Table provides a summary of findings for all the candidate prognostic factors and S1 Appendix includes the corresponding forest plots.

We found high or moderate certainty that the following 35 variables provide valuable prognostic information on mortality outcome ( 

We investigated 96 candidate prognostic factors for severe COVID-19 disease from 131 studies including 28538 patients. S3 Table provides a summary of findings for all the candidate prognostic factors and S2 Appendix includes the corresponding forest plots.

In addition to identified prognostic factors for mortality, we found high or moderate certainty that the following 14 variables provide valuable prognostic information on severe COVID-19 disease outcome (Table 1) 

The remaining variables analysed were: asthma, tuberculosis, HIV infection, immunocompromise, autoimmune disease, malnutrition, chronic liver disease, thyroid disease, chronic gastric disease, chest pain, high fever, cough, rhinorrhea, odynophagia, conjunctivitis, sputum production, enlarged lymph nodes, rash, headache, vomits, diarrhea, anemia, low WBC, low neutrophil count, glomerular filtration rate, blood urea, cystatin C, prothrombin time, APTT time, ferritin, cholinesterase, alanine aminotransferase (ALT), fibrinogen degradation products, globulin, prealbumin, blood glucose, alfa-HBDH, low density lipoprotein (LDL), triglycerides, any abnormal radiologic finding, radiological interstitial pattern, ground glass opacity, crazy paving pattern, radiological evidence of enlarged lymph nodes, bilateral radiological compromise, APACHE (Acute Physiology And Chronic Health Evaluation II), qSOFA (quick sepsis related organ failure assessment).

For all of these variables we found low or very low certainty evidence both for mortality and severe COVID-19 disease. Hence, it is uncertain if these variables provide prognostic value in the context of COVID-19 infected patients.

We performed a sensitivity analysis on mortality outcome using a non-contextualized approach and assuming adjusted estimates as at low risk of being biased (less demanding risk of bias approximation in comparison with the primary analysis) (see methods, risk of bias assessment in S1 Text). The results were similar to the primary analysis. However our certainty increased to moderate or high for some prognostic factors for which we had very low or low certainty: Chest pain, cough, sputum production, anemia, high ferritin, high ALT, increase in blood glucose and high APACHE score.

A second sensitivity analysis in which we set a significantly higher baseline mortality risk (26%) for patients with severe but non-critical COVID-19 disease did not show differences with the primary analysis.

When we found inconsistent results for severe COVID-19 disease outcome (n = 43), we performed subgroup analyses accounting on outcome definition. Observed heterogeneity could not be explained by this analysis for any of the candidate prognostic factors explored (see S3 Appendix).

In this systematic review we evaluated prognostic factors for poor outcome in patients with covid-19 infectious disease. We found 49 variables that provide valuable prognostic information for mortality and/or severe COVID-19 disease. Identified prognostic factors include socio-demographic characteristics (age, male sex and smoking) medical illness and patients history information (comorbidities including chronic respiratory, cardiac and endocrinologic conditions), physical examination findings (respiratory failure related symptoms as well as general clinical condition deterioration), laboratory (multiple biomarkers and alterations in basic laboratory tests) and radiological findings (consolidation pattern and pleural effusion) (Table 1) . Overall the risk of severe COVID-19 disease or death resulted higher in older patients and those with previous medical conditions including COPD and cardiovascular disease as some of the most relevant predictors. Additionally, those patients that presented with clinical signs and symptoms suggesting respiratory failure or laboratory biomarkers showing inflammation or organ damage were also at increased risk of severe COVID-19 disease or death. Radiological features did not show good predictive value.

Our systematic review has a number of strengths. First, it provides the most comprehensive and trustworthy body of evidence up to date as it includes a significant number of studies not included in prior reviews. Secondly, we followed the GRADE approach to summarize and rate the certainty on the evidence. And thirdly, we presented our results both as relative estimates of association as well as absolute risk differences and used the latter to interpret and analyse our results. We consider that the absolute risk modification that can be attributed to a prognostic factor is a critical piece of information for those aiming to make decisions using prognostic information.

Regarding limitations, most of the studies included in this review were not published in peer review journals (only as preprint) at the time we performed the search. We identified most of those studies by cross reference search in google scholar, but it is possible that some may have not been detected by our search strategy. Additionally, given the high publication speed of COVID-19 studies it is probable that new relevant information not included in our review is available at the time our review is published. We aim to address this issue by updating our results in the short term. Although we made efforts to identify data duplication, in many instances it was not clear if studies reported, totally or partially, on the same cohorts of patients hence we assume there is a considerable chance of some degree of data overlap between included publications.

Significant variability in study design, study type, patient eligibility criteria, prognostic factor definition was observed, however, given the huge amount of information analysed, it was not feasible to explore subgroup effects accounting for those differences.

In analysing our results we implemented a minimally contextualized approach for which we arbitrarily set thresholds to define the minimal important risk difference necessary to assume valuable prognostic information. As the degree of contextualization was minimal, we set very low thresholds (near the point of no effect). We acknowledge that readers might find those thresholds inappropriate, hence we also provided relative estimates of association which can be used with alternative thresholds or analytical approximations (e.g partially contextualized approach). In addition, for some candidate prognostic factors, baseline risk could not be adjusted for prevalence which might have resulted in an overestimation or underestimation of the risk difference estimates. Finally, for risk of bias assessment, we defined a set of requirements for dealing with potential confounders that were not previously validated.

We identified multiple systematic reviews addressing prognostic factors in patients with COVID-19 infectious disease [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] . All analysed certain prognostic factors or groups or prognostic factors that we included in the present review, and measured mortality and/or disease severity as outcomes. Most of the reported results are in consonance with our findings with only a few exceptions. Kumar et.al [246] reported diarrhea, productive cough and high ALT as prognostic factors however we found low certainty evidence on those variables in our primary analysis. Wang et.al [249] reported no association between chronic kidney disease and malignancy with poor outcomes in COVID-19 patients however we found that both conditions are associated with an increased risk of mortality and severe COVID-19 disease. Other significant differences of our review in relation to these prior reviews include multiple characteristics that were previously not identified as prognostic factors. In contrast to previous reviews, here we provide both relative and absolute estimates of risk and provide our certainty in those estimates.

Significant information has been published since our search was finalized. An update of the ISARIC registry [252] including 15194 hospitalised patients discharged or dead, the openSA-FELY registry [253] included 17425445 adults potentially exposed to COVID-19 infection and a Chinese registry [254] that included 44672 patients with COVID-19.

These studies identified the following variables as prognostic factors for COVID-19 related mortality: Age, sex (male), obesity, cardiovascular disease, diabetes, arterial hypertension, dyslipidemia, COPD, smoking, malignancy, cerebrovascular disease, dementia and chronic kidney disease. All these variables were captured by our analysis as predictors of COVID-19 related mortality or severe COVID-19 disease for which moderate or high certainty evidence exists. In addition, other prognostic factors were identified by these studies: race (not white) [253] and deprivation [253] , two variables we did not explore, and immunocompromise [253] , asthma [253] , autoimmune diseases [253] , and chronic liver disease [252, 253] , four variables for which we found low certainty evidence.

Our approach considered two clinical scenarios in which we assumed that the prognostic information of each predictor for each outcome could potentially impact decision-making. In patients presenting with mild disease, predicting the risk of progression to severe status could support decisions on the level of healthcare required and more extensive follow up strategies. In the same way, in patients presenting with severe disease, predicting mortality risk could support the use of certain, more aggressive, therapeutic interventions. Clinicians or decisionmakers can use our results to tailor management strategies for patients with COVID-19. For example, they could select a set of prognostic factors for which there is high certainty in a significant risk incremental increase (e.g Age, gender, comorbidities, respiratory failure and myocardial injury) and use them to define hospitalization rules for patients consulting to the emergency department. However, to what extent accounting for these prognostic factors will improve clinically important outcomes is a question that cannot be addressed with our results. Furthermore using information on multiple individual prognostic factors for outcome prediction is challenging. Multivariable models provide a solution to this limitation, however, considering the high demand for accurate risk prediction models for patients with COVID-19 [7] , our work can also provide solid grounds for development of these prognostic tools.

We have identified a set of variables that provide valuable prognostic information in patients with COVID-19 infectious disease. Clinicians and policy makers can use our results to tailor management strategies for patients with this condition while researchers can utilise our findings to develop multivariable prognostic models that could eventually facilitate decision-making and improve patient important outcomes. 

Director-General's remarks at the media briefing on 2019-nCoV on 11

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China

COVID-19 coronavirus pandemic

Prevalence and Severity of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

Global Covid-19 Case Fatality Rates

COVID-19 Report

Prediction models for diagnosis and prognosis of Covid-19 infection: Systematic review and critical appraisal

Prognostic factors for severity and mortality in patients infected with COVID-19: A living systematic review protocol

Use of GRADE for assessment of evidence about prognosis: Rating confidence in estimates of event rates in broad categories of patients

Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes

Assessing bias in studies of prognostic factors

Standard errors of mean, variance, and standard deviation estimators

Conducting meta-analyses in R with the metafor package

Converting an odds ratio to a range of plausible relative risks for better communication of research findings

Converting odds ratio to relative risk in cohort studies with partial data information

CT imaging features of different clinical types of COVID-19: a chinese multicenter study

Leucocyte subsets effectively predict the clinical outcome of patients with COVID-19 pneumonia: A retrospective case-control study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Prognostic factors for COVID-19 pneumonia progression to severe symptom based on the earlier clinical features: A retrospective analysis

Early and critical care in severe patients with COVID-19 in Jiangsu Province, China: A descriptive study

Clinical features and management of severe COVID-19: A retrospective study in Wuxi

Gender differences in patients with COVID-19: Focus on severity and mortality

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Association of obesity with disease severity among patients with COVID-19

Clinical characteristics and CT manifestations of 143 hospitalized patients with 2019 novel coronavirus disease (COVID-19) outside Wuhan: A multi-center study in Taizhou City

Association of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19-related outcome

Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing

Leukopenia predicts risk for death in critically ill patients with COVID-19 in Wuhan, China: A single-centered, retrospective study

Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China

The clinical and chest CT features associated with severe and critical COVID-19 pneumonia

Clinical characteristics of 77 novel coronavirus 2019 infected patients with respiratory failure in the terminal stage in Wuhan

Clinical and transmission characteristics of Covid-19-A retrospective study of 25 cases from a single thoracic surgery department

Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) out of Wuhan

Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China

Critical care for severe COVID-19: A population-based study from a province with low case-fatality rate in China

Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression

Exploring the law of development and prognostic factors of common and severe COVID-19: A retrospective case-control study in 122 patients with complete course of disease

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Neutrophil-to-Lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage

CT Manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity

Association of cardiovascular manifestations with in-hospital outcomes in patients with COVID-19: A hospital staff data

The potential role of IL-6 in monitoring severe case of coronavirus disease 2019

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Association between age and clinical characteristics and outcomes of coronavirus disease 2019

Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity

Neutrophil-to-Lymphocyte Ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Clinical predictors of severity based on an analysis of data of COVID-19 pneumonia

Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54-75 years

Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the province of

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

A machine learning model reveals older age and delayed hospitalization as predictors of mortality in patients with COVID-19

Clinical characteristics and prognostic factors of 148 COVID-19 cases in a secondary epidemic area

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Deep learning-based quantitative computed tomography model in predicting the severity of COVID-19: A retrospective study in 196 patients

Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan

COVID-19 early warning score: A multi-parameter screening tool to identify highly suspected patients

Medication patterns and disease progression among 165 patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: A single-centered, retrospective, observational study

Characteristics of patients with COVID-19 pneumonia admitted to the intensive care unit and predictors of mortality in Wuhan, China: A single-centered retrospective cohort study

Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience

Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 'Diamond Princess' in Japan

Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Characteristics of COVID-19 infection in Beijing

Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan

Epidemiological and clinical features of coronavirus cisease 2019 (COVID-19

Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

Prognostic value of myocardial injury in patients with COVID-19

Coronavirus disease 19 infection does not result in acute kidney injury: An analysis of 116 hospitalized patients from Wuhan, China

Matrix analysis of clinical characteristics and dynamic observation of immunological features in 90 cases of COVID-19

Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in

Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang hospital

Respiratory failure among patients with COVID-19 in Jiangsu province, China: A multicentre retrospective cohort study

Clinical course and outcomes of 344 intensive care patients with COVID-19

Clinical characteristics of patients with severe pneumonia caused by the 2019 novel coronavirus in Wuhan

Clinical features of 69 cases with coronavirus disease

Prevalence of acute kidney injury in severe and critical COVID-19 patients in Wuhan

Epidemiological and clinical characteristics of COVID-19 in Shenzhen, the largest migrant city of China

Epidemical and clinical characteristics of 165 patients infected with SARS-CoV-2 in Fujian province

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study

Association between hypoxemia and mortality in patients with COVID-1

Development and external validation of a prognostic multivariable model on admission for hospitalized patients with COVID-19

Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: A hospital-based retrospective analysis

Epidemiologic features and clinical findings of COVID-19-infected patients in Suzhou

Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong province, China: A multi-center, retrospective, observational study

Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2

Clinical characteristics of coronavirus disease 2019 in Hainan

Clinical features, treatment and outcomes of 218 patients with COVID-19: A retrospective, multicenter study based on clinical classification

The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients

Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension

Blood glucose is a representative of the clustered indicators of multiorgan injury for predicting mortality of COVID-19 in Wuhan

Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 in Yichang, China: A descriptive study

Thrombocytopenia and its association with mortality in patients with COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study

Critically ill patients with COVID-19 in China: A multicenter retrospective observational study

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan

Thin-section chest CT imaging of coronavirus disease 2019 pneumonia: Comparison between patients with mild and severe disease

Association between clinical manifestations and prognosis in patients with COVID-19

Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Risk assessment of progression to severe conditions for patients with COVID-19 pneumonia: A single-center retrospective study

Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study

Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study

Clinical features and outcomes of 221 patients with COVID-19 in Wuhan

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A retrospective analysis

Potential factors for prediction of disease severity of COVID-19 patients

A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan

The clinical data from 19 critically ill patients with coronavirus disease 2019: A single-centered, retrospective, observational study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Digestive involvement of the coronavirus disease 2019: Need attention on the "gut-type" in the novel coronaviral infection

Diarrhea in patients with coronavirus disease 2019: Clinical characteristics, outcomes and implications

Clinical features and a simple model for predicting the mortality of coronavirus disease 2019 patients on admission

Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China

Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension

CT features of SARS-CoV-2 pneumonia according to clinical presentation: A retrospective analysis of 120 consecutive patients from Wuhan City

Short term outcomes and risk factors for mortality in patients with COVID-19 in Wuhan, China: A retrospective study

Potential predictors for disease progression and medication evaluation of 2019 novel coronavirus-infected pneumonia in Wuhan

The incidence, risk factors and clinical outcomes of acute kidney injury in critically ill patients with COVID-19: A multicenter study

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Comorbid diabetes mellitus was associated with poorer prognosis in patients with COVID-19: A retrospective cohort study

Clinical outcomes of patients with 2019-NCoV: A preliminary summary

Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: A retrospective cohort study

Caution on kidney dysfunctions of COVID-19 patients

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

Clinical features and risk factors for the severity of inpatients with COVID-19: A retrospective cohort study

The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Urinalysis, but not blood biochemistry, detects the early renalimpairment in patients with COVID-19

Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19)

Burning Point' is found before the composite end point event happened in critically ill patients with COVID-19: A multicenter retrospective study

A new predictor of disease severity in patients with COVID-19 in Wuhan, China

Correlation between fasting blood glucose level at admission and mortality in COVID-19 patients: A retrospective study

Dose-response association between risk factors and incidence of COVID-19 in 325 hospitalized patients: A multicenter retrospective cohort study

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis

Comparison of severe and non-severe COVID-19 pneumonia: Review and meta-analysis

Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection

Active smoking is not associated with severity of coronavirus disease

Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Incidence, clinical characteristics and prognostic factor of patients with COVID-19: A systematic review and meta-analysis

Laboratory findings, signs and symptoms, clinical outcomes of patients with COVID-19 infection: An updated systematic reeview and meta-analysis. medRxiv 2020; published online March 30

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection

Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis

Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis

Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis

Clinical features of COVID-19 and factors associated with severe clinical course: A systematic review and meta-analysis

The association of lymphocyte count and levels of CRP, D-Dimer, and LDH with severe coronavirus disease 2019 (COVID-19): A meta-analysis. medRxiv 2020; published online

Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): A pooled analysis of published literature

Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: A systematic review and metaanalysis

Comparison of clinical features between critically and noncritically Ill patients in SARS and COVID-19: A systematic review and meta-analysis

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients

Clinical determinants for fatality of 44,672 patients with COVID-19